China Pharma Holdings, Inc. (NYSE:CPHI – Get Free Report)’s stock price dropped 4.4% during trading on Monday . The stock traded as low as $1.07 and last traded at $1.08. 393,419 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 1,922,649 shares. The stock had previously closed at $1.13.
China Pharma Price Performance
The business has a fifty day moving average of $1.09 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.79 and a quick ratio of 0.26. The stock has a market cap of $43.76 million, a PE ratio of -1.96 and a beta of 1.05.
Institutional Trading of China Pharma
A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC increased its stake in China Pharma Holdings, Inc. (NYSE:CPHI – Free Report) by 31.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,426 shares of the company’s stock after buying an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 at the end of the most recent reporting period.
China Pharma Company Profile
China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
Featured Stories
- Five stocks we like better than China Pharma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
